市場調査レポート

商品コード

1448295

子癇前症診断の世界市場規模、シェア、成長分析：検査タイプ別、製品別、エンドユーザー別 - 産業予測（2024年～2031年）

Global Preeclampsia Diagnostics Market Size, Share, Growth Analysis, By Test type(Blood Tests, and Urine Analysis), By Product(Instruments, and Consumables), By End User(Hospitals, Specialty Clinics) - Industry Forecast 2024-2031

出版日: 2024年03月03日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 830,828円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 971,912円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,112,996円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の子癇前症診断の市場規模は、2022年に10億7,000万米ドルとなり、2023年の11億1,000万米ドルから2031年には15億米ドルに拡大し、予測期間中（2024年～2031年）にCAGR3.8%で成長すると予測されています。

子癇前症診断は世界的に広く知られるようになり、市場の顕著な増加に寄与しています。子癇前症として知られる高血圧状態は、産科医療において依然として大きな問題であり、これが正確でタイムリーな診断技術の必要性を高めています。このため、業界の主要参入企業は、子癇前症の早期診断と治療を可能にする最先端の診断ツールの開発に注力せざるを得なくなっています。

子癇前症診断市場の成長は、医療費の増加、新興国市場のヘルスケアインフラの改善、産科医療処置への最先端医療技術の統合にも支えられています。

しかし、最先端の診断技術が高価であることや、一部の地域では質の高いヘルスケアへのアクセスが制限されていることなどの問題が、市場拡大を妨げる可能性があります。今後数年間は、研究開発者が新たなバイオマーカーや非侵襲的診断技術の研究を進めることで、子癇前症診断市場のさらなる発展が期待されます。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主な投資の分析
主な成功要因
競合の程度

市場力学と見通し

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

子癇前症診断の世界市場：検査タイプ別

市場概要
血液検査
尿検査

子癇前症診断の世界市場：製品別

市場概要
機器
消耗品

子癇前症診断の世界市場：エンドユーザー別

市場概要
病院
専門クリニック
診断センターおよびその他

子癇前症診断の世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

F. Hoffmann-La Roche Ltd（Switzerland）
PerkinElmer Inc.（Massachusetts, US）
DRG INSTRUMENTS GMBH（Germany）
Thermo Fisher Scientific Inc.（US）
Diabetomics, Inc.（US）
Metabolomic Diagnostics Ltd.（Ireland）
Sera Prognostics（US）
Siemens Healthineers AG（Germany）
Bayer AG（Germany）
Abbott Laboratories（US）
Agilent Technologies, Inc.（US）
Bio-Rad Laboratories, Inc.（US）
Danaher Corporation（US）
Illumina, Inc.（US）
Natera, Inc.（US）
GE Healthcare（US）
Medtronic plc（Ireland）
Fujifilm Holdings Corporation（Japan）
Mindray Bio-Medical Electronics Co., Ltd.（China）
AstraZeneca plc（UK）

Product Code: SQMIG35D2145

Global Preeclampsia Diagnostics Market size was valued at USD 1.07 Billion in 2022 and is poised to grow from USD 1.11 Billion in 2023 to USD 1.50 Billion by 2031, growing at a CAGR of 3.8% in the forecast period (2024-2031).

Preeclampsia diagnostics are becoming more widely known worldwide, which is contributing to a noticeable increase in the market. The hypertension condition known as preeclampsia is still a major problem in obstetrics, which is driving up need for precise and timely diagnostic techniques. This has forced major industry participants to concentrate on creating cutting-edge diagnostic tools that allow for the early diagnosis and treatment of preeclampsia.

Preeclampsia diagnostics market growth is also being aided by increased healthcare spending, bettering healthcare infrastructure in developing nations, and integrating cutting-edge medical technology into obstetric care procedures.

But issues like the expensive price of cutting-edge diagnostic techniques and some areas' restricted access to high-quality healthcare could potentially impede market expansion. In the upcoming years, more developments in the preeclampsia diagnostics market are anticipated as researchers carry out their investigation into new biomarkers and non-invasive diagnostic techniques.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preeclampsia Diagnostics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preeclampsia Diagnostics Market Segmental Analysis

Market segmentation for preeclampsia diagnostics is based on test type, product, end-user, and region worldwide. It is separated into two categories: urine analysis and blood tests. Consumables and Instruments are included in the product segment. Hospitals, specialty clinics, diagnostic centers, and others are among the end users. The market is divided into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America based on geographic factors.

Drivers of the Global Preeclampsia Diagnostics Market

It has long been difficult to identify hypertension problems in pregnant women in an early stage. The need for novel preeclampsia diagnostic techniques is increasing due to the rise in preeclampsia cases and the urgent need to reduce the rates of maternal and newborn mortality. Point-of-care tests have emerged to diagnose preeclampsia early and have the potential to reduce avoidable hospital hospitalizations and their associated expenses. Major market participants are collaborating strategically to provide better diagnostic solutions in order to address the risk of premature birth. Throughout the anticipated period, the market's trajectory is anticipated to be driven by a wave of product introductions and changing biomarker testing.

Restraints in the Global Preeclampsia Diagnostics Market

Preeclampsia in pregnant women is difficult to diagnose because a single rise in blood pressure is inconclusive. Many expectant women are still ignorant of the term "preeclampsia" and its dangers, despite its rising incidence. Pregnancy-related hypertension frequently goes undiagnosed until symptoms increase, which reduces the number of management choices. at addition to putting women's health at jeopardy, this ignorance about the condition's symptoms and effects raises the risk of newborn mortality.

Market Trends of the Global Preeclampsia Diagnostics Market

A Growing Priority for Early Risk Assessment A significant and noteworthy development in the worldwide preeclampsia diagnostics market is the growing focus on early risk assessment in expectant mothers. The increasing use of biomarker-based testing for the early diagnosis of preeclampsia is being driven by this trend. By utilizing particular biological markers linked to the condition, these tests allow medical professionals to detect possible preeclampsia instances early on. By being proactive, the disease can be better managed and prompt interventions can help improve the results for both the mother and the fetus. The use of biomarker-based diagnostics is in line with the larger goal of lessening the effect of preeclampsia on maternal health and pregnancy outcomes as healthcare systems work to improve maternal care.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Preeclampsia Diagnostics Market by Test type

Market Overview
Blood Tests
and Urine Analysis

Global Preeclampsia Diagnostics Market by Product

Market Overview
Instruments
and Consumables

Global Preeclampsia Diagnostics Market by End User

Market Overview
Hospitals
Specialty Clinics
Diagnostic Centers & Others

Global Preeclampsia Diagnostics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer Inc. (Massachusetts, US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DRG INSTRUMENTS GMBH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Diabetomics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metabolomic Diagnostics Ltd. (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sera Prognostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Holdings Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mindray Bio-Medical Electronics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments